RG
CPRX

Renaissance Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Renaissance Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-445,215
Closed -$11M – 242
2026
Q1 		$11M Buy
445,215
+98,847
+29% +$2.35M 0.46% 63
2025
Q4 		$8.08M Sell
346,368
-9,654
-3% -$215K 0.32% 78
2025
Q3 		$7.01M Buy
356,022
+26,965
+8% +$555K 0.26% 111
2025
Q2 		$7.14M Buy
329,057
+76,772
+30% +$1.81M 0.28% 87
2025
Q1 		$6.12M Buy
252,285
+49,525
+24% +$1.12M 0.27% 81
2024
Q4 		$4.23M Buy
+202,760
New +$4.36M 0.18% 105

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Group's CPRX Position: Q2 2026 in Review

Renaissance Group sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 445,215 shares — an estimated $11M sold.

Renaissance Group first reported a position in CPRX in Q4 2024 and held it in 6 quarters. The position peaked at $11M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Renaissance Group reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Renaissance Group sold 445,215 Catalyst Pharmaceutical shares in Q2 2026, an estimated $11M.
  • Renaissance Group first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • Renaissance Group's Catalyst Pharmaceutical position peaked at $11M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Renaissance Group's 13F filing for Q2 2026, filed 13 Aug 2026.